Abstract
To investigate cardiac effects of imatinib at an extended follow-up (median 12.4 months), 12 chronic myeloid leukemia patients underwent cardiac screening. No significant changes on the frequency of cardiovascular signs and symptoms, electrocardiographic abnormalities, echocardiographic measurements and BNP levels were observed. Median ejection fraction was 67% at baseline versus 68% at follow-up (median intra-patient change 0.5%). Median BNP levels were 8.3 versus 7.3pg/mL (median intra-patient change 0.2pg/mL). Troponin I measures were below the lower limit of detection, whereas strain measures were similar to healthy control. This pilot study suggests that it is probably safe to perform cardiac monitoring on an annual basis.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Echocardiography
-
Electrocardiography
-
Female
-
Follow-Up Studies
-
Heart / drug effects*
-
Heart Failure / chemically induced
-
Heart Failure / drug therapy*
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Male
-
Middle Aged
-
No-Observed-Adverse-Effect Level
-
Pilot Projects
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Prospective Studies
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Survival Rate
-
Treatment Outcome
-
Troponin I / blood
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Troponin I
-
Imatinib Mesylate